A Study of HGS1029 in Subjects With Relapsed or Refractory Lymphoid Malignancies

Inclusion Criteria: * Confirmed relapsed/refractory lymphoid malignancies * Previously treated with at least 2 therapeutic regimens * ECOG performance \< 2. * Life expectancy of at least 3 months * Adequate renal function * Adequate hematologic status * Adequate liver function * Transfusion independent Exclusion Criteria: * Received other therapy (biological or drug) to treat cancer within 4 weeks prior to starting treatment with HGS1029 or who exhibit persistent clinical evidence of cancer treatment toxicity * The use of systemic corticosteroids within 1 week of starting treatment with HGS1029 * Evidence of active bacterial, viral or fungal infection within 2 weeks before starting treatment with HGS1029 * Known HIV infection * Positive for hepatitis B surface antigen or positive hepatitis C antibody * Grade 2 or greater neuropathy * Pregnant female or nursing mother * Males or females who do not agree to use effective contraception during the study and through at least 30 days after the last dose of HGS1029